Jpmorgan Chase & CO Avidity Biosciences, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.23 Trillion
  • Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 450,144 shares of RNA stock, worth $14.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
450,144
Previous 467,085 3.63%
Holding current value
$14.9 Million
Previous $21.5 Million 38.98%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$29.08 - $52.5 $492,644 - $889,402
-16,941 Reduced 3.63%
450,144 $13.1 Million
Q3 2024

Dec 26, 2024
SELL
$37.21 - $48.14 $535,637 - $692,975
-14,395 Reduced 2.99%
467,085 $21.5 Million
Q3 2024

Nov 08, 2024
SELL
$37.21 - $48.14 $535,637 - $692,975
-14,395 Reduced 2.99%
467,085 $21.5 Million
Q2 2024

Dec 26, 2024
BUY
$22.73 - $40.85 $327,198 - $588,035
14,395 Added 3.08%
481,480 $19.7 Million
Q2 2024

Aug 12, 2024
SELL
$22.73 - $40.85 $9.36 Million - $16.8 Million
-411,994 Reduced 46.11%
481,480 $19.7 Million
Q1 2024

Dec 26, 2024
BUY
$9.16 - $25.52 $3.91 Million - $10.9 Million
426,389 Added 91.29%
893,474 $22.8 Million
Q1 2024

May 10, 2024
SELL
$9.16 - $25.52 $681,769 - $1.9 Million
-74,429 Reduced 7.69%
893,474 $22.8 Million
Q4 2023

Dec 26, 2024
BUY
$4.87 - $9.37 $2.44 Million - $4.69 Million
500,818 Added 107.22%
967,903 $8.76 Million
Q4 2023

Feb 12, 2024
SELL
$4.87 - $9.37 $13,631 - $26,226
-2,799 Reduced 0.29%
967,903 $8.76 Million
Q3 2023

Nov 14, 2023
BUY
$6.3 - $11.35 $2.65 Million - $4.77 Million
420,695 Added 76.49%
970,702 $6.19 Million
Q2 2023

Aug 11, 2023
SELL
$10.62 - $17.34 $31,615 - $51,621
-2,977 Reduced 0.54%
550,007 $6.1 Million
Q1 2023

May 18, 2023
BUY
$15.35 - $25.65 $1.27 Million - $2.12 Million
82,550 Added 17.55%
552,984 $8.49 Million
Q1 2023

May 11, 2023
BUY
$15.35 - $25.65 $5.3 Million - $8.86 Million
345,516 Added 276.59%
470,434 $7.22 Million
Q4 2022

Feb 13, 2023
BUY
$10.06 - $22.66 $138,797 - $312,640
13,797 Added 12.42%
124,918 $2.77 Million
Q3 2022

Nov 14, 2022
SELL
$15.46 - $23.43 $239,027 - $362,251
-15,461 Reduced 12.21%
111,121 $1.81 Million
Q2 2022

Aug 11, 2022
BUY
$11.18 - $20.5 $284,721 - $522,073
25,467 Added 25.19%
126,582 $1.84 Million
Q1 2022

May 11, 2022
SELL
$14.2 - $23.78 $145,635 - $243,887
-10,256 Reduced 9.21%
101,115 $1.87 Million
Q4 2021

Feb 10, 2022
BUY
$20.4 - $28.66 $1.72 Million - $2.42 Million
84,266 Added 310.89%
111,371 $2.65 Million
Q3 2021

Nov 12, 2021
BUY
$18.16 - $25.21 $492,226 - $683,317
27,105 New
27,105 $668,000

Others Institutions Holding RNA

# of Institutions
252
Shares Held
110M
Call Options Held
197K
Put Options Held
184K
View Full List

About Avidity Biosciences, Inc.

RNA Quotes by TradingView
  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.72B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email